2020 - Member of the National Academy of Medicine (NAM)
Antoni Ribas mainly focuses on Melanoma, Internal medicine, Cancer research, Immunology and Vemurafenib. His biological study spans a wide range of topics, including V600E, Trametinib and Drug resistance. His studies deal with areas such as Surgery and Oncology as well as Internal medicine.
His Surgery research incorporates elements of Gastroenterology and Hazard ratio. His Cancer research research also works with subjects such as
Antoni Ribas spends much of his time researching Melanoma, Internal medicine, Cancer research, Immunology and Oncology. His Melanoma research integrates issues from Cancer, MEK inhibitor and Trametinib. He focuses mostly in the field of Internal medicine, narrowing it down to matters related to Surgery and, in some cases, Gastroenterology and Hazard ratio.
His work focuses on many connections between Cancer research and other disciplines, such as Immune checkpoint, that overlap with his field of interest in Tumor microenvironment. His work in Immunology tackles topics such as Cytotoxic T cell which are related to areas like CD8. The concepts of his Oncology study are interwoven with issues in Metastatic melanoma, Phases of clinical research, Adverse effect, Randomized controlled trial and Dacarbazine.
Antoni Ribas focuses on Melanoma, Cancer research, Internal medicine, Oncology and Immunotherapy. His Melanoma research focuses on Adverse effect and how it connects with Toxicity. His work deals with themes such as Immune checkpoint, T cell, Immune system and Cancer, which intersect with Cancer research.
His research in Internal medicine tackles topics such as Trametinib which are related to areas like Mutant. His Oncology study combines topics from a wide range of disciplines, such as Survival analysis, Clinical endpoint, Vemurafenib and Dosing. His Immunotherapy research is multidisciplinary, relying on both Epitope, Antigen, Computational biology and T-cell receptor.
His primary areas of study are Melanoma, Internal medicine, Cancer research, Oncology and Dabrafenib. Particularly relevant to Vemurafenib is his body of work in Melanoma. His Cancer research research incorporates themes from Agonist, Cancer immunotherapy, Immune system, Immunotherapy and Cell therapy.
His Immune system study incorporates themes from Odds ratio, Cancer, Wnt signaling pathway and MEDLINE. His work is dedicated to discovering how Oncology, Biomarker are connected with Monoclonal, Carcinoma, Lung cancer and Clinical endpoint and other disciplines. The Dabrafenib study which covers Trametinib that intersects with Mutant and Regimen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen.
The New England Journal of Medicine (2011)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance.
The New England Journal of Medicine (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh;Christina L. Harview;Jennifer H. Yearley;I. Peter Shintaku.
Inhibition of mutated, activated BRAF in metastatic melanoma.
Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas.
The New England Journal of Medicine (2010)
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi.
The New England Journal of Medicine (2013)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan.
The New England Journal of Medicine (2014)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis;Jonathan E Zuckerman;Chung Hang J Choi;David Seligson.
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez.
The New England Journal of Medicine (2012)
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian;Hubing Shi;Qi Wang;Xiangju Kong.
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski.
The New England Journal of Medicine (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: